[Pemphigus herpetiformis following D-penicillamine in a patient with HLA B8].
A 57-year-old patient with rheumatoid arthritis, who was being treated with D-penicillamine, developed a bullous eruption 2 months after the onset of treatment. On the basis of the clinical, histological and immunofluorescent findings, the diagnosis of herpetiform pemphigus was made. The eruptions disappeared within 2 weeks after the discontinuation of D-penicillamine treatment. During the 16-month follow-up period there was no recurrence. It is noteworthy that a patch test with potassium iodide was positive and that testing for HLA antigens revealed HLA B8, A1, A2, and BW39.
Weltfriend
S
S
Department of Dermatology, Beilinson Medical Center, Petach-Tikv, Israel.
Ingber
A
A
David
M
M
Sandbank
M
M
D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology; D003874:Dermatitis Herpetiformis / Q000139:chemically induced* / Q000473:pathology; D003875:Drug Eruptions / Q000209:etiology*; D015235:HLA-B Antigens / Q000032:analysis; D015795:HLA-B8 Antigen; D006801:Humans; D008297:Male; D008875:Middle Aged; D010392:Pemphigus / Q000139:chemically induced* / Q000473:pathology; D010396:Penicillamine / Q000009:adverse effects* / Q000627:therapeutic use; D012867:Skin / Q000473:pathology
D015235:HLA-B Antigens; D015795:HLA-B8 Antigen; D010396:Penicillamine
Pemphigus herpetiformis nach D-Penicillamin bei einem Patienten mit HLA B8.